Cicletanine

Cicletanine is a furopyridine low-ceiling diuretic drug, usually used in the treatment of hypertension.[1] The drug is manufactured by Ipsen and marketed by Recordati (in France) under the trade name Tenstaten.

Cicletanine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
Protein binding97.3%
Elimination half-life7.9 h
Identifiers
  • 3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.158.583
Chemical and physical data
FormulaC14H12ClNO2
Molar mass261.71 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C3OCc2c3cnc(c2O)C
  • InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3 checkY
  • Key:CVKNDPRBJVBDSS-UHFFFAOYSA-N checkY
  (verify)

It appears to be more potent in salt-sensitive hypertension.[2]

Mechanism

It can inhibit protein kinase C.[3]

References
  1. Jean Sassard (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
  2. Bagrov AY; Dmitrieva RI; Dorofeeva NA; et al. (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". J. Hypertens. 18 (2): 209–15. doi:10.1097/00004872-200018020-00012. PMID 10694190. S2CID 35374482.
  3. Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension. 41 (3): 505–11. doi:10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.